FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran)

The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and the public that preliminary results from a recently completed clinical study suggest that a 32 mg single intravenous dose of ondansetron (Zofran, ondansetron hydrochloride, and generics) may affect the electrical activity of the heart (QT interval prolongation), which could pre-dispose patients to develop an abnormal and potentially fatal heart rhythm known as Torsades de Pointes.

Source: FDA Center for Drug Evaluation and Research - What's New - January 8, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news